{
  "id": "deffd84d5f00cf73",
  "title": "STAT+: New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment",
  "description": "Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology meeting.",
  "content": "Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology meeting.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2025/12/07/gilead-arcellx-multiple-myeloma-treatment-anito-cel-promising-data-ash/?utm_campaign=rss",
  "published_at": "2025-12-07T15:56:41+00:00",
  "fetched_at": "2025-12-08T00:22:54.837391+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": null,
  "raw_data": {
    "title": "STAT+: New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment",
    "description": "Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology meeting.",
    "url": "https://www.statnews.com/2025/12/07/gilead-arcellx-multiple-myeloma-treatment-anito-cel-promising-data-ash/?utm_campaign=rss",
    "published": "2025-12-07T15:56:41+00:00",
    "source": "STAT"
  }
}